Navigation Links
Vaccine Made from Live bird flu virus vaccine Offers Protection to Animals

According to US researchers three experimental vaccines using live but weakened versions of the H5N1 bird flu virus seemed to offer protection against infection//, and could probably be the solution to to stockpile vaccines ahead of a pandemic.

They said tests on people were already underway, and this could lead to the start of a repository of vaccines against various potential strains of pandemic influenza.

The researchers wrote in the online journal Public Library of Science-Medicine, "We have been developing live, attenuated influenza virus vaccines because they have properties that make them attractive vaccines for the prevention of pandemic influenza in humans."

This vaccine takes only a single dose of a live, weakened vaccine to stimulate a good immune response according to researchers.

Another advantage that lay with such vaccines is the benefit of cross-protection, which meant that the vaccine protects against other, similar strains of the virus. This was useful especially because the current flu mutates a little every year, forcing vaccine makers to reformulate annually.

Director of National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci said, "If an influenza pandemic were imminent or underway, we would need a vaccine that could stimulate immunity quickly, preferably with a single dose."

Health experts fear a mutation of the H5N1 avian flu virus that is now killing birds globally, into a form that easily infects people, sparking a pandemic that could kill millions.

Although H5N1 has infected only 244 people and killed 143, governments, companies and other organizations are racing to produce a vaccine.

So far the vaccines that have been developed use pieces of DNA from the viruses while some others use a virus that is completely inactivated, or killed. Since most seasonal flu vaccines use a killed virus there is little chances of cross-pr otection.

Maryland-based MedImmune Inc has engineered a live but weakened virus that is delivered as a nasal spray instead of injected by needle.

Researchers from MedImmune worked with teams at the National Institutes of Health and the U.S. Department of Agriculture to make a live H5N1 vaccine. The teams were led by Dr. Kanta Subbarao of NIAID using three different strains of H5N1 dating back to when the dangerous form first emerged in Hong Kong in 1997.

The researchers reported that mice that got a single dose of vaccine, given in a nose spray, all survived normally lethal doses of H5N1. It was found that mice and ferrets given two doses of vaccine were not only protected but that their bodies also suppressed the virus.

The team artificially constructed their viruses using weakened flu strains and added key proteins from H5N1 strains that infected people in 1997,2003 and 2004.

Even more amazing was the usual low-tech approach to produce this vaccine, growing it in chicken eggs, that is in the same way that seasonal flu vaccine is produced.

MedImmune said in June it was already testing one of the vaccines in human volunteers, in what is known as a Phase I safety trial.

The researchers noted it is not possible to predict which strain of H5N1 or any other influenza virus might cause a pandemic. There are hundreds of different possible combinations of hemagglutinin (the "H" in a flu strain's name) and neuraminidase (the "N").

The researchers wrote, "If the vaccine candidates described in this paper elicit a broadly cross-reactive protective immune response in humans, they would support the approach of developing one or two pandemic vaccine candidates for each subtype (H4 through H16) …."


NLA
'"/>




Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... May 19, 2016 At the 18 ... Meeting in Amsterdam , (May 15-19), Elekta ... clinically-proven radiosurgery system available, has been used in the ... brain tumors, vascular malformations and functional disorders. ... 75,000 patients every year in hundreds of leading hospitals ...
Breaking Medicine Technology: